Surmodics Inc
NASDAQ:SRDX

Watchlist Manager
Surmodics Inc Logo
Surmodics Inc
NASDAQ:SRDX
Watchlist
Price: 39.68 USD 0.4% Market Closed
Market Cap: 568.6m USD
Have any thoughts about
Surmodics Inc?
Write Note

Surmodics Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Surmodics Inc
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Surmodics Inc
NASDAQ:SRDX
Operating Income
-$5.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Operating Income
$2.9B
CAGR 3-Years
7%
CAGR 5-Years
6%
CAGR 10-Years
6%
Boston Scientific Corp
NYSE:BSX
Operating Income
$2.9B
CAGR 3-Years
20%
CAGR 5-Years
10%
CAGR 10-Years
11%
Stryker Corp
NYSE:SYK
Operating Income
$4.8B
CAGR 3-Years
11%
CAGR 5-Years
8%
CAGR 10-Years
8%
Abbott Laboratories
NYSE:ABT
Operating Income
$7B
CAGR 3-Years
-7%
CAGR 5-Years
10%
CAGR 10-Years
11%
Intuitive Surgical Inc
NASDAQ:ISRG
Operating Income
$2.1B
CAGR 3-Years
5%
CAGR 5-Years
10%
CAGR 10-Years
14%
No Stocks Found

Surmodics Inc
Glance View

Market Cap
568.4m USD
Industry
Health Care

Surmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic immunoassay tests and microarrays. The company is headquartered in Eden Prairie, Minnesota and currently employs 389 full-time employees. The firm operates through two segments: Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices, as well as drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that includes coronary, peripheral, neurovascular and structural heart, among others. The IVD segment designs, develops and manufactures component products and technologies for diagnostic immunoassay, as well as molecular tests and biomedical research applications, with products that include protein stabilization reagents, substrates, surface coatings and antigens.

SRDX Intrinsic Value
15.49 USD
Overvaluation 61%
Intrinsic Value
Price

See Also

What is Surmodics Inc's Operating Income?
Operating Income
-5.6m USD

Based on the financial report for Sep 30, 2024, Surmodics Inc's Operating Income amounts to -5.6m USD.

Back to Top